Tri Locum Partners’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Tri Locum Partners’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-96,274	Closed	-$9.82M	–	91
2023 Q2	$9.82M	Buy	96,274 +29,068	+43%	+$2.75M	3.65%	8
2023 Q1	$6.11M	Sell	67,206 -74,260	-52%	-$4.36M	1.86%	20
2022 Q4	$5.37M	Buy	+141,466	New	+$4.87M	2.17%	15

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Tri Locum Partners's RETA Position: Q3 2023 in Review

Tri Locum Partners sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 96,274 shares — an estimated $9.82M sold.

Tri Locum Partners first reported a position in RETA in Q4 2022 and held it in 3 quarters. The position peaked at $9.82M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Tri Locum Partners reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Tri Locum Partners sold 96,274 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $9.82M.
Tri Locum Partners first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2022 and held it in 3 quarters.
Tri Locum Partners's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $9.82M in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Tri Locum Partners's 13F filing for Q3 2023, filed 14 Nov 2023.